文献速递前列腺癌

基于前列腺特异性抗原筛查对前列腺癌发病率和死亡率影响的详细评估:欧洲前列腺癌筛查随机研究鹿特丹部分21年随访结果

A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer.
PubMed 文献 · Eur Urol · 2023-04-05

该研究基于欧洲前列腺癌筛查随机研究鹿特丹部分,1993至2000年随机纳入42376名55-74岁男性,主要分析55-69岁男性(n=34831)。中位随访21年后,筛查组前列腺癌特异性死亡率率比0.73(95%CI 0.61-0.88),转移性疾病率比0.67(95%CI 0.58-0.78),均支持筛查。

要点

  • 中位随访21年,筛查组前列腺癌特异性死亡率率比0.73(95%CI 0.61-0.88),支持筛查。
  • 预防一例前列腺癌死亡需邀请246人、诊断14人;预防一例转移需邀请121人、诊断7人。
  • 随机分组时年龄≥70岁男性中,前列腺癌特异性死亡率率比1.18(95%CI 0.87-1.62),无统计学差异。

核心结论

  • 随访21年,绝对转移和死亡率降低持续增加,获益-危害比此前更有利;数据不支持70-74岁开始筛查,并表明重复筛查至关重要。

研究设计与样本

  • 欧洲前列腺癌筛查随机研究鹿特丹部分,1993至2000年随机纳入42376名55-74岁男性,主要分析55-69岁男性(n=34831),筛查组每4年接受一次基于前列腺特异性抗原的筛查,采用意向筛查分析和泊松回归计算率比。

主要发现

  • 中位随访21年,前列腺癌特异性死亡率率比0.73(95%CI 0.61-0.88),支持筛查;预防一例前列腺癌死亡需邀请人数246,需诊断人数14。
  • 转移性前列腺癌率比0.67(95%CI 0.58-0.78),支持筛查;预防一例转移需邀请人数121,需诊断人数7。
  • 随机分组时年龄≥70岁男性中,前列腺癌特异性死亡率率比1.18(95%CI 0.87-1.62),无统计学差异。
  • 筛查组中,仅筛查一次和年龄超过74岁筛查年龄 cutoff 的特定男性群体观察到更高的前列腺癌特异性死亡率和转移性疾病发生率。

临床怎么用

  • 作者认为数据不支持70-74岁开始筛查,并表明重复筛查至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Considering the long natural history of prostate cancer (PCa), long-term results of the European Randomised Study of Screening for PCa (ERSPC) are crucial. OBJECTIVE: To provide an update on the effect of prostate-specific antigen (PSA)-based screening on PCa-specific mortality (PCSM), metastatic disease, and overdiagnosis in the Dutch arm of the ERSPC. DESIGN, SETTING, AND PARTICIPANTS: Between 1993 and 2000, a total of 42376 men, aged 55-74 yr, were randomised to a screening or a control arm. The main analysis was performed with men aged 55-69 yr (n = 34831). Men in the screening arm were offered PSA-based screening with an interval of 4 yr. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Intention-to-screen analyses with Poisson regression were used to calculate rate ratios (RRs) of PCSM and metastatic PCa. RESULTS AND LIMITATIONS: After a median follow-up of 21 yr, the RR of PCSM was 0.73 (95% confidence interval [CI]: 0.61-0.88) favouring screening. The numbers of men needed to invite (NNI) and needed to diagnose (NND) to prevent one PCa death were 246 and 14, respectively. For metastatic PCa, the RR was 0.67 (95% CI: 0.58-0.78) favouring screening. The NNI and NND to prevent one metastasis were 121 and 7, respectively. No statistical difference in PCSM (RR of 1.18 [95% CI: 0.87-1.62]) was observed in men aged ≥70 yr at the time of randomisation. In the screening arm, higher rates of PCSM and metastatic disease were observed in men who were screened only once and in a selected group of men above the screening age cut-off of 74 yr. CONCLUSIONS: The current analysis illustrates that with a follow-up of 21 yr, both absolute metastasis and mortality reduction continue to increase, resulting in a more favourable harm-benefit ratio than demonstrated previously. These data do not support starting screening at the age of 70-74 yr and show that repeated screening is essential. PATIENT SUMMARY: Prostate-specific antigen-based prostate cancer screening reduces metastasis and mortality. Longer follow-up shows fewer invitations and diagnoses needed to prevent one death, a positive note towards the issue of overdiagnosis.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. de Vos II, Meertens A, Hogenhout R, et al. A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer. Eur Urol. 2023. PMID: 37029074. doi:10.1016/j.eururo.2023.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。